- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00769808
Technolas 217z Laser With Zyoptix Aspheric Algorithm Used for the LASIK Treatment of Myopia and Myopic Astigmatism.
24. August 2020 aktualisiert von: Bausch & Lomb Incorporated
A Prospective Trial to Evaluate the Safety and Effectiveness of the Bausch & Lomb Technolas® 217z Laser With Zyoptix® Aspheric Algorithm When Used for the LASIK Treatment of Myopia and Myopic Astigmatism
The purpose of this study is to evaluate the safety and effectiveness of the Bausch & Lomb Technolas 217z laser with the investigational Zyoptix Aspheric Algorithm when used for LASIK treatment of myopia and myopic astigmatism.
Studienübersicht
Status
Abgeschlossen
Bedingungen
Intervention / Behandlung
Studientyp
Interventionell
Einschreibung (Tatsächlich)
72
Phase
- Unzutreffend
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
Ontario
-
Toronto, Ontario, Kanada, M5X1C8
- Lasik MD, 130 King Street
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
18 Jahre und älter (Erwachsene, Älterer Erwachsener)
Akzeptiert gesunde Freiwillige
Nein
Studienberechtigte Geschlechter
Alle
Beschreibung
Inclusion Criteria:
- Subjects who were of legal age (at least 18) and had full legal capacity to volunteer.
- Subjects must be willing to have both eyes treated with the laser.
- Subjects must have up to -12.00D of absolute spherical myopia (not spherical equivalent) with up to -6.00D of refractive astigmatism, with a spherical equivalent up to -15.00D as measured by manifest subjective refraction.
- Subjects who had less than 0.75 D of difference in the preoperative manifest spherical equivalent and cycloplegic spherical equivalent subjective refractions.
(Manifest subjective refractions adjusted for optical infinity were used.)
- High contrast, manifest best spectacle-corrected distance logMAR visual acuity correctable to at least 0.3 in both eyes, and must not differ between eyes by more than 1 line (5 letters).
- Contact lens wearers must have 2 Orbscan measurements and 2 manifest subjective refractions taken preoperatively at least 1 week apart.
- Contact lens wearers must have gas permeable lenses discontinued for at least 3 weeks and soft lenses discontinued for at least 2 weeks prior to the preoperative evaluation.
Exclusion
- Subjects with uncorrected visual acuity better than 20/40 (Snellen) or 0.3 logMAR
- Subjects who were immuno-compromised or had a diagnosis of connective tissue disease, clinically significant atopic disease, diabetes, autoimmune diseases and other acute or chronic illnesses that increased the risk to the subject or could have confounded the outcomes of this study.
- Subjects with uncontrolled glaucoma or glaucoma who were under treatment in the study eye or with ocular hypertension.
- Subjects who demonstrated evidence of retinal vascular disease.
- Subjects who have an ocular muscle disorder including strabismus or nystagmus, or other disorders that affected fixation.
- Subjects who were at risk for angle closure or who had a potentially occludable angle, as evidenced by a shallow anterior chamber on slit lamp exam, confirmed by gonioscopy as deemed necessary by the study Investigator.
- Subjects who had undergone previous intraocular or corneal surgery of any kind, including any type of excimer laser surgery for either refractive or therapeutic purposes.
- Subjects who were taking systemic medications likely to affect wound healing such as corticosteroids or anti-metabolites or any other medications that may increase the risk to the subject or confound the outcomes of this study.
- Subjects for whom the combination of their preoperative corneal thickness and the planned operative parameters for the LASIK procedure could have resulted in less than 250 microns of remaining posterior corneal thickness below the flap postoperatively.
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Technolas 217z Excimer Laser
Bausch & Lomb Zyoptix Aspheric Algorithm for LASIK correction of myopia and myopic astigmatism.
|
LASIK correction of myopia and myopic astigmatism
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage of Eyes With Uncorrected High Contrast Distance Visual Acuity of 20/40 or Better
Zeitfenster: 3 months
|
3 months
|
|
|
Percentage of Eyes With Manifest Subjective Refraction (MRSE) Within ± 1.00 Diopter (D) and 0.50 D of Emmetropia
Zeitfenster: 3 months
|
Manifest refractions (eyeglass prescriptions) have three components: sphere, cylinder, and axis.
Sphere and cylinder are both expressed in diopters, which is a continuous measure of the focusing power needed to make the image sharp on the retina.
Manifest refraction spherical equivalent (MRSE) is equal to sphere + ½ x cylinder.
It is expressed in diopters (D).
|
3 months
|
|
Preservation of Manifest Best Corrected High Contrast Distance Visual Acuity
Zeitfenster: Baseline, 3 months
|
Mean change in best-corrected high contrast distance visual acuity.
Corrected means spectacle corrected.
Visual acuity (VA) was reported as letters read correctly, and the letters read were converted to logarithm of the minimum angle of resolution (logMAR) acuity.
The participant read rows of letters on a standard LogMAR chart until the participant misses 3 letters on a row with 5 letters.
The total number of correct letters were recorded.
A decrease in the number of correct letters indicates a decrease in visual acuity.
Acuity was averaged across visits.
|
Baseline, 3 months
|
|
Percentage of Eyes With Manifest Best-corrected Distance Photopic Visual Acuity Decrease of 2 or More Lines
Zeitfenster: 3 months
|
3 months
|
|
|
Percentage of Eyes With > 2.00 Diopter of Induced Postoperative Refractive Cylinder
Zeitfenster: 3 months
|
Manifest refractions (eyeglass prescriptions) have three components: sphere, cylinder, and axis.
Sphere and cylinder are both expressed in diopters, which is a continuous measure of the focusing power needed to make the image sharp on the retina.
Manifest refraction spherical equivalent (MRSE) is equal to sphere + ½ x cylinder.
It is expressed in diopters (D).
|
3 months
|
|
Percentage of Eyes That Had High Contrast Best Spectacle Corrected Visual Acuity (HCBSCVA) of 20/20 or Better at Baseline Had a Visual Outcome Worse Than 20/40 at 3 Months
Zeitfenster: 3 months
|
Corrected means spectacle corrected.
Visual acuity (VA) was reported as letters read correctly, and the letters read were converted to logarithm of the minimum angle of resolution (logMAR) acuity.
The participant read rows of letters on a standard LogMAR chart until the participant misses 3 letters on a row with 5 letters.
The total number of correct letters were recorded.
A decrease in the number of correct letters indicates a decrease in visual acuity.
Acuity was averaged across visits.
|
3 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage Change From Baseline in Higher Order Aberrations.
Zeitfenster: Baseline, 3 months
|
The aberrations in the eye's optical system were measured over the entire pupil by the Bausch & Lomb Zywave II WaveFront Aberrometer, a Hartmann-Shack type device.
The pupil should have been at least 6 mm in diameter using 2.5% phenylephrine as a dilating agent to maximize the pupil diameter and hence the amount of wavefront information collected by the Zywave II.
The wavefront data was then fitted with Zernike polynomials representing the 2nd, 3rd, 4th and 5th order Zernike terms.
These terms represent the wavefront aberration of the eye.
|
Baseline, 3 months
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Ermittler
- Hauptermittler: Mark Cohen, MD, Lasik MD
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn
1. August 2008
Primärer Abschluss (Tatsächlich)
1. März 2010
Studienabschluss (Tatsächlich)
1. März 2010
Studienanmeldedaten
Zuerst eingereicht
8. Oktober 2008
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
8. Oktober 2008
Zuerst gepostet (Schätzen)
9. Oktober 2008
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
11. September 2020
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
24. August 2020
Zuletzt verifiziert
1. August 2020
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 564
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .